EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Association between pregnancy, reproductive hormones, and lung cancer risk: a systematic review

Eleni-Maria Sotiropoulou, Antigoni Sarantaki, Vasiliki Epameinondas Georgakopoulou, Giannoula Kyrkou, Athina Diamanti

Folia Medica · 2025-10-22 · 67 (5)

DOI: 10.3897/folmed.67.e156329 ↗
AbstractBibliografische Angaben

Abstract

 Abstract Lung cancer remains the leading cause of cancer-related mortality worldwide, with unique epidemiological and molecular patterns observed in women. Smoking is the primary risk factor for lung cancer. However, a significant number of cases in female never-smokers suggest other contributors, including reproductive and hormonal factors. This systematic review synthesizes evidence on the association between pregnancy, reproductive hormones, and lung cancer risk, with a focus on pregnancy-associated lung cancer (PALC). Key findings include the protective role of higher parity, later menopause, and prolonged reproductive periods, attributed to hormonal stabilization and immune modulation. PALC, though rare, presents distinct challenges due to diagnostic delays and the need for pregnancy-specific treatment strategies. Molecular profiling highlights a high prevalence of actionable mutations, such as anaplastic lymphoma kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) mutations, offering potential targets for therapy. However, the analysis also underscores significant gaps in knowledge. Confounding factors, particularly smoking, and heterogeneity in study designs limit causal inferences. Future research should prioritize large-scale cohort studies and mechanistic investigations to elucidate hormonal and genetic interactions. Clinically, integrating reproductive history into lung cancer risk models could enhance early detection and personalized management strategies, particularly in high-risk subgroups. This review contributes to the growing understanding of hormonal influences on lung cancer, emphasizing their potential as biomarkers and therapeutic targets.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →